Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-56021927 plus ADT versus ADT alone in low-volume metastatic hormone-sensitive prostate cancer
RBR-6txnfvPhase 3Not yet recruiting
- Sponsor
- Hospital de Amor
- Start
- Nov 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing JNJ-56021927 plus ADT with Placebo plus ADT (2 arms). Planned start Nov 2015; status: not yet recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on RBR-6txnfv.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-6txnfv.